FDA authorises marketing of diagnostic test that uses novel technology to detect MRSA bacteria

FDA

5 December 2019 - Today, the U.S. FDA authorised marketing of a new diagnostic test based on bacterial viability and novel technology to detect Methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonisation, a widespread cause of hospital-acquired infections. 

The cobas vivoDx MRSA diagnostic test may allow health care professionals to evaluate patients for colonisation with MRSA bacteria more quickly than traditional culture-based techniques when such testing is needed.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Diagnostic agent